Assignee
VIELA BIO INC
US·7 granted patents·22 pending applications·19 citations·filing 2017–2025
Top patents by PatentIndex Score
29 records- 0188US11072652B2ILT7 binding molecules and methods of using the sameVIELA BIO INC·Filed 2017·Granted Jul 27, 2021·5 cites·24 claims
- 0287US11306145B2Binding molecules specific for FcγRIIA and uses thereofVIELA BIO INC·Filed 2017·Granted Apr 19, 2022·10 cites·13 claims
- 0387US2024417460A1Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseVIELA BIO INC·Filed 2024·Application pending·0 cites
- 0485US11673950B2ILT7 binding molecules and methods of using the sameVIELA BIO INC·Filed 2021·Granted Jun 13, 2023·1 cites·22 claims
- 0580US11512127B2Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseasesVIELA BIO INC·Filed 2019·Granted Nov 29, 2022·2 cites·21 claims
- 0678US2023242619A1Compositions comprising a tn3 scaffold and methods of using the sameVIELA BIO INC·Filed 2022·Application pending·0 cites
- 0777US11104720B2Nucleic acids encoding a Tn3 scaffold comprising a CD40L-specific monomer subunitVIELA BIO INC·Filed 2018·Granted Aug 31, 2021·1 cites·22 claims
- 0874US11746153B2Binding molecules specific for FcγRIIA and uses thereofVIELA BIO INC·Filed 2022·Granted Sep 5, 2023·0 cites·9 claims
- 0974US11555062B2Methods of administering a composition comprising a Tn3 scaffold and a CD40L-specific monomerVIELA BIO INC·Filed 2021·Granted Jan 17, 2023·0 cites·39 claims
- 1073US2021061906A1Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseVIELA BIO INC·Filed 2020·Application pending·0 cites
- 1172US2025257120A1Compositions comprising a tn3 scaffold and methods of using the sameVIELA BIO INC·Filed 2025·Application pending·0 cites
- 1272US2023250167A1Ilt7 binding molecules and methods of using the sameVIELA BIO INC·Filed 2023·Application pending·0 cites
- 1371US2025019408A1Cd40l antagonist and uses thereofVIELA BIO INC·Filed 2024·Application pending·0 cites
- 1464US2026070997A1Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjögren's syndromeVIELA BIO INC·Filed 2025·Application pending·0 cites
- 1563US2018273621A1Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseVIELA BIO INC·Filed 2018·Application pending·0 cites
- 1661US2024383991A1Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjögren's syndromeVIELA BIO INC·Filed 2024·Application pending·0 cites
- 1759US2023406928A1Methods of treating neuromyelitis optica spectrum disorderVIELA BIO INC·Filed 2022·Application pending·0 cites
- 1858US2024301058A1Inebilizumab and methods of using the same in the treatment or prevention of igg4-related diseaseVIELA BIO INC·Filed 2024·Application pending·0 cites
- 1958US2021340200A1Cd40l antagonist and uses thereofVIELA BIO INC·Filed 2019·Application pending·0 cites
- 2058US2026027212A1Formulations comprising an immunoglobulin-like transcript 7 (ilt7)-binding proteinVIELA BIO INC·Filed 2023·Application pending·0 cites
- 2157US2024368294A1Cd40l-specific tn3-derived scaffolds for use in the treatment and prevention of rheumatoid arthritisVIELA BIO INC·Filed 2024·Application pending·0 cites
- 2256US2023287114A1Use of an anti-cd19 antibody to treat autoimmune diseaseVIELA BIO INC·Filed 2023·Application pending·0 cites
- 2353US2024084024A1Cd40l antagonist and uses thereof in the treatment of lupus nephritisVIELA BIO INC·Filed 2023·Application pending·0 cites
- 2453US2023279092A1Immunocytokines for treatment of autoimmune and inflammatory conditionsVIELA BIO INC·Filed 2021·Application pending·0 cites
- 2551US2024270842A1Use of an anti-cd19 antibody to treat myasthenia gravisVIELA BIO INC·Filed 2022·Application pending·0 cites
- 2651US2023151093A1Methods of treating immune mediated pulmonary injuryVIELA BIO INC·Filed 2022·Application pending·0 cites
- 2751US2022403020A1Methods of treatment using ilt7 binding proteinsVIELA BIO INC·Filed 2022·Application pending·0 cites
- 2849US2024287176A1Methods of treatment of autoimmune disorders using ilt7 binding proteinsVIELA BIO INC·Filed 2022·Application pending·0 cites
- 2943US2022204617A1Use of an anti-cd19 antibody to treat autoimmune diseaseVIELA BIO INC·Filed 2020·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →